Loading...
The association between depot medroxyprogesterone acetate (DMPA) and loss of BMD led the U.S. FDA and Health Canada to issue warnings about this agent’s use for contraception. Recently, the National Institute of Public Health of Quebec organized a meeting to allow experts in women’s heath, rheumatology, orthopedic surgery, rehabilitative medicine, and endocrinology to review the evidence and reach consensus on recommendations for DMPA use.
Several studies (including a manufacturer-sponsored, FDA-requested, prospective cohort study) have confirmed that bone loss occurs in adult and adolescent DMPA users. Nine studies showed that such loss is reversible and echoes the temporary BMD reduction that occurs during pregnancy and lactation. The grou…